| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer
1 company
Olivier Danos last filed a Form 4 in February 2025, as Chief Scientific Officer at RGNX. Olivier Danos's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 226,348 shares of RGNX. The RGNX filings lean toward selling, a net 22,000 shares.
Olivier Danos has 15 Form 4 filings on record from March 2017 to February 2025, all as Chief Scientific Officer at Regenxbio (RGNX), 2017–2025.
The 37 reported transactions were 13 stock awards, 9 option or other derivative awards, 6 open-market sales and 5 tax withholdings, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.4M.
The largest open-market sale was 20,000 shares of RGNX at an average $63.80 on October 8, 2018, about $1.3M.
Shares as reported in the last Form 4 for each company; the most recent is from February 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.